Recent 8-K filings for HSCS
Highest-materiality recent filing
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
- Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
- The reverse stock split affects both common stock and warrants, with split-adjusted trading expected at market open on May 17, 2024.
-
HeartSciences annual meeting approves director, stock plan, auditor; officer exculpation fails
Andrew Simpson re-elected Class III director with 577,840 for, 107,738 withheld, 1,288,285 broker non-votes.
-
HeartSciences COO and Board Member Mark Hilz passes away at 67
Mark Hilz, COO, Corporate Secretary and Board member, died April 1, 2026 after an illness.
-
HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances
No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.
-
HeartSciences issues $3.6M 12% promissory note to Streeterville Capital, netting $3M
Company entered Note Purchase Agreement with Streeterville Capital for $3,605,000 promissory note, netting $3,000,000 after $600,000 OID and $5,000 expenses.
-
HeartSciences adopts standard indemnification agreements for directors and officers
Board approved form of Indemnification Agreement for all directors and executive officers on December 15, 2025.
-
HeartSciences reports no Q2 revenue, $2M cash; submits wavECG to FDA
No meaningful revenue for FQ2 2026; cash and equivalents $2.0M, shareholders' equity $4.2M as of Oct 31, 2025.
-
Board approved Amendment No. 3 to 2023 Equity Incentive Plan, increasing authorized shares from 1M to 1.25M plus annual evergreen.
-
HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity
Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.
-
HeartSciences regains Nasdaq minimum equity compliance; delisting risk cleared
Received formal notice on Sept 16, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
-
HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform
No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
-
HeartSciences raises $5.4M in Reg A offering, exchanges $1.8M debt for shares
Received $5.4M gross proceeds from Reg A offering of units at $3.50; 1,556,409 units issued as of Sep 5, 2025.
-
HeartSciences raises $5.2M in Reg A offering and exchanges $1.655M debt for equity
Gross proceeds of $5.2M from offering of 1,484,440 Units at $3.50/Unit as of Aug 22, 2025.
-
HeartSciences increases ATM equity offering limit to $25M in amended distribution agreement
Amendment No. 3 to Equity Distribution Agreement raises maximum offering from $15M to $25M of common stock.
-
HeartSciences raises $4.3M in Reg A offering; exchanges $1.1M debt for equity
Gross proceeds of $4.3M from 1,241,188 units at $3.50/unit in Regulation A offering.
-
HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform
Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
-
HeartSciences updates Regulation A offering: $2.8M raised, 797K units issued, 486K shares converted
Gross proceeds of $2.8M from 797,452 Units at $3.50/unit, each consisting of Series D Preferred and a warrant.
-
HeartSciences expands equity plan to 1M shares, grants RSUs and options tied to FDA clearance
Board approved amendment to 2023 Equity Incentive Plan increasing maximum shares to 1,000,000; subject to shareholder vote at next annual meeting.
-
HeartSciences amends bylaws to add jury waiver, 3% derivative threshold
Adds jury trial waiver for 'internal entity claims' under Texas Business Organizations Code.
-
HeartSciences launches $15M offering of Series D Preferred and warrants
Placement Agent Agreement with Digital Offering LLC for best-efforts offering of up to 4,285,714 Units at $3.50 each.
-
FDA granted Breakthrough Device designation for HeartSciences' Aortic Stenosis AI-ECG algorithm.
-
HeartSciences granted foundational US patent for ECG-based heart function assessment
USPTO granted patent covering estimation of heart function measures via ECG; critical for early detection of heart disease.
-
HeartSciences files Certificate of Designations for Series D Preferred Stock in $15M offering
Designates 4,285,714 shares of Series D Convertible Preferred Stock for the Unit offering (each Unit: one Series D share + warrant to buy common at $5.00).
-
Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M
Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
-
HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum
Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.
-
HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025
No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.
-
HeartSciences grants 117K options to execs and directors at $3.33 strike
CEO Andrew Simpson and COO Mark Hilz each receive 45,000 options; CFO Danielle Watson receives 9,000.
-
HeartSciences withdraws S-1 registration statement for proposed public offering
Withdrew Registration Statement on Form S-1 filed June 7, 2023 (as amended).
-
No revenue in Q2 FY2025; cash and equivalents $4.1M, shareholders' equity ~$4.0M at Oct 31, 2024.
-
HeartSciences stockholders ratify auditor and approve adjournment at annual meeting
Ratified Haskell & White LLP as auditor for FY2025: 413,499 for, 9,896 against, 1,116 abstain.
-
Heart Test Laboratories officially changes name to HeartSciences Inc.; Nasdaq trading starts Oct 23
Name change from Heart Test Laboratories, Inc. to HeartSciences Inc. effective Oct 11, 2024, confirmed by Texas Secretary of State.
-
Filed Certificate of Amendment with Texas on October 11, 2024 to change name to HeartSciences Inc.
-
Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
-
Issued $2.51M unsecured promissory note to Streeterville Capital; 8.5% interest, 18-month maturity, $500K OID.
-
Heart Test Labs extends $500k loan maturity to Sep 2025; accelerates interest payments
Principal $500,000 at 12% compounded annually; maturity extended from Sep 30, 2024 to Sep 30, 2025.
-
HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates
Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.
-
HeartSciences regains Nasdaq minimum bid price compliance; hearing cancelled
Nasdaq notified HeartSciences on June 3, 2024 that it regained compliance with $1.00 minimum bid price requirement.
-
Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27
Nasdaq delisting action stayed pending oral hearing on June 27, 2024.
-
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
-
Heart Test Laboratories to effect 1-for-100 reverse stock split on May 17, 2024
Reverse stock split of common stock and warrants at 1-for-100 ratio, effective at market open on May 17, 2024.
-
Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material